# Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

> **NCT06754553** · — · NOT_YET_RECRUITING · sponsor: **University Hospital, Strasbourg, France** · enrollment: 100 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **BEHAVIORAL:** Assessment of severity of ICD (impulse control disorders)
- **BEHAVIORAL:** Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
- **BEHAVIORAL:** Assessment of quality of life
- **BEHAVIORAL:** Assessment of depression
- **BEHAVIORAL:** Assessment of cognition
- **BEHAVIORAL:** Assessment of severity of Parkinson Disease
- **PROCEDURE:** Cardiac monitoring

## Key facts

- **NCT ID:** NCT06754553
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-01-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754553, "Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06754553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*